LNPs are designed to stay in the circulation long enough to accumulate at disease sites, such as the liver or cancerous tumors. Through a process called endocytosis, cells take up the LNPs which allows them to migrate into the cell. The LNPs then undergo an interaction within the cell and the RNAi trigger molecules are released, mediating RNAi.
To realize the tremendous therapeutic potential of RNAi-based drugs, effective delivery is critical. Our proprietary delivery technology:
Additionally, multi-dosing with LNP has proven to be well-tolerated with treatments out to one year.
Our manufacturing process is rapid, scalable, and highly reproducible – enabling the commercialization of LNP-based products. In collaboration with the U.S. Department of Defense (DoD) on our TKM-Ebola program, we developed a number of innovations for our LNP delivery technology, such as a “commercial-scale” manufacturing process and ability to lyophilize (freeze-dry) LNP.
We continue to demonstrate leadership in the industry by making innovations to our LNP technology to enable RNAi therapeutics. These innovations include, but are not limited to: